Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-3400, 21885 | Other Identifier | IUCPQ |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to demonstrate the superiority in clinical performances of a dual artery compression device (Terry-2 band) compared to a standard radial artery-only hemostasis device (HemoSTOP).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dual Artery Compression | Experimental | time to hemostasis and incidence of radial artery occlusion will be monitored while using a dual artery compression device (Terry-2-band) to achieve hemostasis. |
|
| Radial Artery-Only | Active Comparator | time to hemostasis and incidence of radial artery occlusion will be monitored while using the device currently approved by the institution (Hemo-Stop) and following institutional protocols for hemostasis. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hemostasis | Device | Compression device to achieve hemostasis. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of RAO after transradial approach (TRA) at hospital discharge | To determine whether the use of a dual artery compression decreases the rate of radial artery occlusion after transradial catheterization. | up to 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of radial artery patent-hemostasis during hemostasis | To determine the conservation of blood flow through the radial artery during compressive hemostasis | throughout intervention, up to 180 minutes |
| Patient comfort during hemostasis as assessed on a visual scale |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Olivier F Bertrand | Contact | 4186568711 | olivier.bertrand@crhl.ulaval.ca | |
| Michèle Jadin | Contact | 4186568711 | 3007 |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IUCPQ - Laval Hospital | Recruiting | Québec | G1V 4G5 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the level of patient comfort in relation to the device used |
| throughout intervention, up to 30 days |
| Rates of complications such as repeat bleeding and hematoma (EASY Scale) | To determine the incidence of complications in relation to the device used. Bleeding, spasm and presence of hematomas will be evaluated. | throughout intervention, up to 30 days |
| Nursing involvement in hemostasis management for sensitivity analysis on cost assessment | To determine the overall nursing involvement (time per nurse per patient) in hemostasis monitoring from end of procedure to patient discharge for a cost-benefit evaluation. | throughout intervention, up to 24 hours |